HK1022831A1 - Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates - Google Patents

Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates

Info

Publication number
HK1022831A1
HK1022831A1 HK00101773A HK00101773A HK1022831A1 HK 1022831 A1 HK1022831 A1 HK 1022831A1 HK 00101773 A HK00101773 A HK 00101773A HK 00101773 A HK00101773 A HK 00101773A HK 1022831 A1 HK1022831 A1 HK 1022831A1
Authority
HK
Hong Kong
Prior art keywords
piperidino
solvates
salts
pharmaceutical composition
oral administration
Prior art date
Application number
HK00101773A
Other languages
English (en)
Inventor
Bernard Abramovici
Christian Condamine
Jean-Claude Gromenil
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HK1022831A1 publication Critical patent/HK1022831A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK00101773A 1997-03-28 2000-03-22 Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates HK1022831A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9703835A FR2761266B1 (fr) 1997-03-28 1997-03-28 Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
PCT/FR1998/000631 WO1998043636A1 (fr) 1997-03-28 1998-03-27 Composition pharmaceutique pour administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs s olvates

Publications (1)

Publication Number Publication Date
HK1022831A1 true HK1022831A1 (en) 2000-08-25

Family

ID=9505295

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101773A HK1022831A1 (en) 1997-03-28 2000-03-22 Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates

Country Status (41)

Country Link
US (1) US6893659B2 (es)
EP (1) EP0969832B1 (es)
JP (1) JP3805797B2 (es)
KR (1) KR100479521B1 (es)
CN (1) CN1126543C (es)
AR (1) AR012160A1 (es)
AT (1) ATE202703T1 (es)
AU (1) AU740486B2 (es)
BR (1) BR9808429A (es)
CA (1) CA2284051C (es)
CO (1) CO4950527A1 (es)
CY (2) CY2275B1 (es)
CZ (1) CZ292129B6 (es)
DE (1) DE69801045T2 (es)
DK (1) DK0969832T3 (es)
DZ (1) DZ2453A1 (es)
EE (1) EE04578B1 (es)
ES (1) ES2161049T3 (es)
FR (1) FR2761266B1 (es)
GR (1) GR3036382T3 (es)
HK (1) HK1022831A1 (es)
HR (1) HRP980163B1 (es)
HU (1) HU224838B1 (es)
ID (1) ID22973A (es)
IL (1) IL131818A (es)
IS (1) IS1960B (es)
MY (1) MY121733A (es)
NO (1) NO321615B1 (es)
NZ (1) NZ337736A (es)
PL (1) PL191107B1 (es)
PT (1) PT969832E (es)
RS (1) RS49606B (es)
RU (1) RU2193886C2 (es)
SA (1) SA98190095B1 (es)
SI (1) SI0969832T1 (es)
SK (1) SK283265B6 (es)
TR (1) TR199902236T2 (es)
TW (1) TW565450B (es)
UA (1) UA49056C2 (es)
WO (1) WO1998043636A1 (es)
ZA (1) ZA982609B (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002247019C1 (en) * 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
NZ580387A (en) 2004-07-12 2011-06-30 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
BRPI0518241A (pt) 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
JP2008523684A (ja) * 2004-12-07 2008-07-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ インテリジェントポースボタン
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009682A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical formulations comprising substituted pyrazoline compounds
EP1745783A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
ES2348374B1 (es) * 2005-07-15 2011-08-02 Laboratorios Del Dr Esteve, S.A. Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
US7786144B2 (en) 2006-05-31 2010-08-31 Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
JP2009538874A (ja) * 2006-05-31 2009-11-12 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 選択的カンナビノイドｃｂ１受容体アンタゴニストとしての硫黄含有ピラゾール誘導体
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2913018A1 (fr) * 2007-02-23 2008-08-29 Sanofi Aventis Sa Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
FR2919868A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
IT1390848B1 (it) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20110852A1 (es) 2008-10-30 2011-11-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1393930B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PT3004138T (pt) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10554908B2 (en) * 2016-12-05 2020-02-04 Facebook, Inc. Media effect application
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10562896B2 (en) 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
IL277608B2 (en) * 2018-04-02 2023-09-01 Chemocentryx Inc Prodrugs of conjugated c5ar antagonists
CA3119509A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
TW202227417A (zh) 2020-08-18 2022-07-16 美商默沙東藥廠 雙環庚烷吡咯啶之食慾素受體促效劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR656354A (fr) * 1927-11-07 1929-05-07 British Maxium Ltd Procédé de purification des métaux
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US5087454A (en) * 1990-07-30 1992-02-11 American Home Products Corporation Ibuprofen tablet
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient

Also Published As

Publication number Publication date
IS1960B (is) 2004-11-15
JP3805797B2 (ja) 2006-08-09
CZ344199A3 (cs) 2000-01-12
SI0969832T1 (es) 2001-12-31
ES2161049T3 (es) 2001-11-16
DZ2453A1 (fr) 2004-07-14
BR9808429A (pt) 2000-05-23
CA2284051A1 (en) 1998-10-08
NO321615B1 (no) 2006-06-12
ID22973A (id) 1999-12-23
DE69801045T2 (de) 2002-03-14
NO994706L (no) 1999-11-25
RS49606B (sr) 2007-06-04
PL335942A1 (en) 2000-05-22
RU2193886C2 (ru) 2002-12-10
SA98190095B1 (ar) 2006-06-18
AU740486B2 (en) 2001-11-08
US6893659B2 (en) 2005-05-17
FR2761266B1 (fr) 1999-07-02
SK130999A3 (en) 2000-03-13
UA49056C2 (uk) 2002-09-16
TR199902236T2 (xx) 1999-12-21
CY2006005I1 (el) 2009-11-04
SK283265B6 (sk) 2003-04-01
CN1126543C (zh) 2003-11-05
HU224838B1 (en) 2006-03-28
CY2006005I2 (el) 2009-11-04
NO994706D0 (no) 1999-09-27
WO1998043636A1 (fr) 1998-10-08
ZA982609B (en) 1998-09-30
JP2001517224A (ja) 2001-10-02
EE04578B1 (et) 2006-02-15
US20030003145A1 (en) 2003-01-02
NZ337736A (en) 2001-02-23
CY2275B1 (en) 2003-07-04
HRP980163B1 (en) 2002-10-31
HRP980163A2 (en) 1998-12-31
DE69801045D1 (de) 2001-08-09
IL131818A (en) 2003-07-31
FR2761266A1 (fr) 1998-10-02
AU7052798A (en) 1998-10-22
CZ292129B6 (cs) 2003-08-13
EP0969832A1 (fr) 2000-01-12
CN1251524A (zh) 2000-04-26
MY121733A (en) 2006-02-28
KR100479521B1 (ko) 2005-03-30
DK0969832T3 (da) 2001-10-22
CO4950527A1 (es) 2000-09-01
YU47099A (sh) 2002-06-19
CA2284051C (en) 2005-01-11
ATE202703T1 (de) 2001-07-15
EE9900441A (et) 2000-04-17
PT969832E (pt) 2001-11-30
IS5190A (is) 1999-09-23
HUP0001894A3 (en) 2002-01-28
TW565450B (en) 2003-12-11
PL191107B1 (pl) 2006-03-31
EP0969832B1 (fr) 2001-07-04
HUP0001894A2 (hu) 2001-04-28
KR20010005752A (ko) 2001-01-15
IL131818A0 (en) 2001-03-19
GR3036382T3 (en) 2001-11-30
AR012160A1 (es) 2000-09-27

Similar Documents

Publication Publication Date Title
GR3036382T3 (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
AU7052698A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
IL115097A0 (en) Pharmaceutical compositions adapted for oral administration
HUP0004050A3 (en) Itraconazole exhibiting improved solubility, a method of preparing the same and pharmaceutical composition for oral administration comprising the same
EP0873749A4 (en) GELLED PRODUCTS FOR ORAL ADMINISTRATION
HUP9603064A2 (en) New oral pharmaceutical dosage form
IL117728A0 (en) Pharmaceutical compositions for transdermal administration
HUP0101437A3 (en) Oral pharmaceutical extended release dosage form
HUP9901037A3 (en) Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds
IL122705A (en) 2-(4-Susbstituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
IL145559A0 (en) Tolperison-containing pharmaceutical preparation for oral administration
HK1015677A1 (en) Rapamycin formulations for oral administration
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
EP0953359A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HUP0003341A3 (en) Rapamycin formulations for oral administration
HUP9901349A3 (en) Oxazolidinone derivatives, their preparation and pharmaceutical compositions containing these compounds
AU3860797A (en) Pharmaceutical formulations for oral administration
PL325509A1 (en) Therapeutic agent for oral administration
HUP0101012A3 (en) Pharmaceutical composition for oral administration
EP1188440A4 (en) MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
GB9418029D0 (en) Pharmaceutical compositions for oral administration
SI0927031T1 (en) Pharmaceutical preparation containing nimesulide for oral administration
AU3570195A (en) Pharmaceutical composition of fantofarone for oral administration
SI1043976T1 (sl) Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem
IE900393L (en) Pharmaceutical compositions for oral administration

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140327